Siga

Siga(SIGA)

NEW YORK, NY
Biotechnology
WebsiteLinkedInCareers Page

Focus: Small Molecules

Siga is a life sciences company focused on Small Molecules.

Infectious Diseases
Funding Stage
PUBLIC
Open Jobs
0

Products & Portfolio (2)

TPOXX
tecovirimat monohydrate
Peak
ORAL · CAPSULE
Cytochrome P450 3A Inducers
2018
0
TPOXX
tecovirimat monohydrate
Peak
INTRAVENOUS · SOLUTION
Cytochrome P450 3A Inducers
2022
0

Pipeline & Clinical Trials

TPOXX 200Mg Capsule
Smallpox
N/A
Clinical Trials (1)
NCT03972111A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With Smallpox
N/A
N/A
Clinical Trials (1)
NCT05380752Tecovirimat Intravenous Treatment for Orthopox Virus Exposure
N/A
ST-246
Healthy
Phase 1
Clinical Trials (1)
NCT00431951Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers
Phase 1
ST-246 Days 1 - 3
Orthopoxviral Disease
Phase 1
Clinical Trials (1)
NCT00728689Phase I Trial of an Investigational Small Pox Medication
Phase 1
Phase 2
Clinical Trials (1)
NCT00907803Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246
Phase 2
Tecovirimat
Smallpox
Phase 2
Clinical Trials (1)
NCT04957485Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS
Phase 2
Tecovirimat Oral Capsule
MPOX
Phase 3
Clinical Trials (1)
NCT05534984Study of Tecovirimat for Human Mpox Virus
Phase 3
tecovirimat
Smallpox
Phase 3
Clinical Trials (1)
NCT02474589A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat
Phase 3
Phase 3
Clinical Trials (1)
NCT04971109Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days
Phase 3
Tecovirimat
Smallpox
Phase 4
Clinical Trials (1)
NCT04485039Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders
Phase 4
Phase 4
Clinical Trials (1)
NCT04392739Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG
Phase 4

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Founded: 2000
Portfolio: 2 approved products, 11 clinical trials
Top TAs: Infectious Diseases
Publications: 25 in PubMed
SEC Filings: 2 available
Portfolio Health
Peak2 (100%)
2 total products
Therapeutic Area Focus
Marketed
Pipeline

Financials (FY2025)

Revenue
$140M26%
R&D Spend
$16M(12%)27%
Net Income
$68M
Cash
$155M
Source: SEC 10-K Filing